The Limitless Future of RNA Therapeutics.

Frontiers in Bioengineering and Biotechnology
Tulsi Ram DamaseJohn P Cooke


Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively simple to manufacture, and can target previously undruggable pathways. It is a disruptive therapeutic technology, as small biotech startups, as well as academic groups, can rapidly develop new and personalized RNA constructs. In this review we discuss general concepts of different classes of RNA-based therapeutics, including antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, and messenger RNA. Furthermore, we provide an overview of the RNA-based therapies that are currently being evaluated in clinical trials or have already received regulatory approval. The challenges and advantages associated with use of RNA-based drugs are also discussed along with various approaches for RNA delivery. In addition, we introduce a new concept of hospital-based RNA therapeutics and share our experience with establishing such a platform at Houston Methodist Hospital.


Jan 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·M L Stephenson, P C Zamecnik
Mar 23, 1990·Science·J A WolffP L Felgner
Aug 30, 1990·Nature·A D Ellington, J W Szostak
Jul 1, 1995·Clinical Microbiology Reviews·F R Vogel, N Sarver
Jul 1, 1993·European Journal of Immunology·F MartinonP Meulien
Mar 10, 2001·Nucleic Acids Research·T A VickersS M Freier
Mar 22, 2002·Journal of Virology·Itaru AnrakuAlexander A Khromykh
Sep 5, 2002·Nature Reviews. Drug Discovery·Andrew L Hopkins, Colin R Groom
Jan 24, 2003·Nature·Eugene Russo
Jun 28, 2003·Journal of Virology·Tracey J HarveyAlexander A Khromykh
Aug 29, 2003·Oncogene·Raghuvir S TomarPreet M Chaudhary
Feb 13, 2004·The Journal of Biological Chemistry·Hongjiang WuStanley T Crooke
Feb 3, 2005·Nature Reviews. Drug Discovery·Vladimir P Torchilin
Mar 7, 2006·Nature Reviews. Drug Discovery·Eugene W M NgAnthony P Adamis
Jul 11, 2006·Nature Biotechnology·James O McNamaraPaloma H Giangrande
Dec 7, 2007·The Journal of Clinical Investigation·James O McNamaraEli Gilboa
Jul 19, 2008·Chemistry & Biology·Claudia M DollinsBruce A Sullenger
Sep 18, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Katalin KarikóDrew Weissman
Sep 22, 2009·Trends in Biotechnology·Zuzana AntosovaTomas Macek
Sep 29, 2009·Colloids and Surfaces. B, Biointerfaces·Avnesh KumariSubhash C Yadav
Jan 9, 2010·Annual Review of Pharmacology and Toxicology·C Frank Bennett, Eric E Swayze
May 27, 2010·Indian Journal of Pharmaceutical Sciences·P SaraswatB P Nagori
Mar 22, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alexey BerezhnoyEli Gilboa
Apr 10, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yechezkel Barenholz
Jul 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·Dan ZhengAmy S Paller
Oct 3, 2012·The Journal of Cell Biology·Frank RigoC Frank Bennett
May 7, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Pinaki R DesaiMandip Singh
Jul 3, 2013·Human Gene Therapy. Clinical Development·Laura M BryantJames M Wilson
Jul 23, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Kunn HadinotoWean Sin Cheow

❮ Previous
Next ❯


May 30, 2021·Thérapie·Dominique Deplanque, Odile Launay
Jul 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Layla R GoddardAnastasia J Callaghan
Aug 28, 2021·Biomolecular NMR Assignments·Yaping LiuSarah C Keane
Sep 2, 2021·FEBS Letters·Ting-Yu LinSebastian Glatt
Nov 11, 2021·Accounts of Chemical Research·Longfei Jia, Shu-Bing Qian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Current Opinion in Cardiology
Christian BoadaJohn P Cooke
Nature Reviews. Drug Discovery
Sarah Crunkhorn
© 2021 Meta ULC. All rights reserved